Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis
Journal
Osteoporosis International
Journal Volume
17
Journal Issue
3
Pages
373-378
Date Issued
2006
Author(s)
Abstract
This study compared the clinical efficacy, safety, and tolerability of daily subcutaneous injections of teriparatide and salmon calcitonin in the treatment of postmenopausal women with established osteoporosis in Taiwan. This 6-month, multicenter, randomized, controlled study enrolled 63 women with established osteoporosis. They were randomized to receive either teriparatide 20 μg or calcitonin 100 IU daily in an open-label fashion. Lumber spine, femoral neck, total hip bone mineral density (BMD), and biochemical markers of bone turnover were measured, and adverse events and tolerability were recorded. The results at 6 months showed that patients using teriparatide had larger mean increases in spinal BMD than those who used calcitonin (4.5% vs. 0.1%), but the BMD changes in these two groups at the femoral neck and the total hip were not significant. There were also larger mean increases in bone markers in the teriparatide group than in the calcitonin group (bone specific alkaline phosphatase 142% vs. 37%; osteocalcin 154% vs. 23%). We conclude that teriparatide has more positive effects on bone formation than salmon calcitonin, as shown by the larger increments of lumbar spine BMD and bone formation markers, and caused only mild adverse events and no significant change in liver, kidney or hematological parameters. Compared with the published global results, teriparatide seems to be equally effective and safe to use in this Asian population. ? International Osteoporosis Foundation and National Osteoporosis Foundation 2006.
Subjects
Bone mineral density; Calcitonin; Osteoporosis; Teriparatide
SDGs
Other Subjects
alkaline phosphatase; biochemical marker; nitrogen; osteocalcin; parathyroid hormone[1-34]; salcatonin; urea; abnormally high substrate concentration in blood; adult; aged; alkaline phosphatase blood level; article; Asia; bone density; bone turnover; cardiovascular disease; clinical trial; comparative study; constipation; controlled clinical trial; controlled study; dizziness; drug effect; drug efficacy; drug eruption; drug safety; drug tolerability; dyspnea; female; femur neck; gastrointestinal symptom; heart palpitation; hip; human; hypercalcemia; hyperuricemia; liver disease; lumbar spine; major clinical study; measurement; multicenter study; musculoskeletal disease; neurologic disease; open study; ossification; postmenopause; postmenopause osteoporosis; priority journal; protein blood level; randomization; randomized controlled trial; side effect; statistical significance; systemic disease; Taiwan; treatment duration; treatment outcome; urea nitrogen blood level; vasodilatation; vomiting; Aged; Bone Density; Bone Density Conservation Agents; Calcitonin; Chi-Square Distribution; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Taiwan; Teriparatide
Type
journal article